CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 70 enrolled
Drug / intervention
darapladib +1 moredrug
Likely dose
darapladib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01067339
NCT01067339Phase 3Completed
CompareCT.gov

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Mayo Clinic·interventional·Posted Feb 11, 2010·Updated Apr 18, 2017

In Brief

A Phase 3 clinical trial evaluating darapladib and placebo for Endothelial Dysfunction. Completed, enrolled 70 participants across 1 site.

Detailed Summary

AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is directly connected to IRB 08-008161 as a specific aim of the National Institute of Health (NIH) grant. Participants may either consent to and qualify for AIM I and AIM II (IRB 08-008161) or have a cardiac catheterization with acetylcholine testing in the Cardiac Catheterization Laboratory at Mayo Clinic in Rochester, Minnesota to be considered for this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndothelial Dysfunction
CountriesUnited States
CollaboratorsGlaxoSmithKline, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2010
Enrollment StartFeb 4, 2010
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 16.4 years ago

Interventions

darapladibdrug

darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration

placebodrug

placebo, by mouth, once daily for six months